Replies to post #212554 on Biotech Values

[DewDiligence]

AMGN/ADXS start phase-1 trial of ADXS-NEO (neoantigen vaccine)—tumor types are NSCLC, CRC, and H&N:

https://clinicaltrials.gov/ct2/show/NCT03265080

[DewDiligence]

AMGN’s updated webpage on I-O pipeline—scan down for ADXS-NEO discussion:

https://www.amgenscience.com/immuno-oncology-research/

Although the webpage itself has changed a lot since I last looked several months ago, the description of ADXS-NEO is the same—it still says:

An Investigational New Drug application for ADXS-NEO was accepted by the FDA in March 2017, paving the way for the start of phase 1 studies.